T Cell Engaging Antibody Circuits (TEAC ): Focusing Immune Activation to the Cancer Cell Surface to Widen the Therapeutic Index. Time: 10:00 am day: Day One. Details: Traditional T cell redirecting therapies can kill tumor cells in therapeutically useful ways but are limited by off-target and on-target/off-tumor toxicities, 11/13/2019 · These data suggest T-cell engaging antibody circuits is a new approach that could be safely applied toward AML. TEAC agents do not directly activate T-cells and CD123xCD33 TEAC pairs do not activate PBMC or monocytes. However, CD123xCD33 TEACs show strong activity against AML cell lines and primary CD123+CD33+ AML cells.
T cell engaging antibody circuits (TEACs) is a novel immune cell engaging platform that allows for exquisite targeting of cancer cells with minimal targeting of healthy cells. Beyond T-cells, our interest is to use this platform to engage the innate compartment. For the effective design of TEAC molecules that can redirect innate immune responses, we developed a.
11/26/2019 · T cell-engaging immunotherapies are changing the landscape of current cancer care. However, suitable target antigens are scarce, restricting these strategies to very few tumor types. Here, we…
